Use of Cannabinoids for Spasticity and Pain Management in MS

  • Hardeep Chohan
  • Ariele L. Greenfield
  • Vijayshree Yadav
  • Jennifer Graves
Multiple Sclerosis and Related Disorders (P Villoslada, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Multiple Sclerosis and Related Disorders

Opinion statement

Several randomized trials have demonstrated potential benefit of cannabis derivatives in the symptomatic treatment of multiple sclerosis (MS) patients. These provide class 1 and 2 evidence for cannabinoid product use for spasticity and pain in these patients. The precise best ratio or doses are not yet clear. The safety and potential long-term effects of these products on cognitive function in people with MS have not been evaluated. Since short-term memory and processing speed can be significantly impaired in many people with MS, the concern of potential cognitive impairment related to cannabis products needs consideration in clinical care and should be addressed in longer, prospective studies.


Multiple sclerosis Cannabinoids Spasticity Pain Tetrahydrocannabinol Cannabidiol 


Compliance with Ethical Standards

Conflict of Interest

Hardeep Chohan, Ariele L Greenfield, and Vijayshree Yadav each declare no potential conflicts of interest.

Jennifer Graves reports grants from Genentech and Race to Erase MS.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Alexander SPH. Therapeutic potential of cannabis-related drugs. Prog Neuro-Pharmacol Biol Psychiatry. 2016;64:157–66.CrossRefGoogle Scholar
  2. 2.
    Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the Uniter States: historical perspectives, current trends, and future directions. J Opioid Manag. 2009;5(3):153–68.PubMedGoogle Scholar
  3. 3.
    Maione S, Costa B, Vincenzo DM. Endocannabinoids: a unique opportunity to develop multitarget analgesics. Pain. 2013;154:S87–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61–5.CrossRefPubMedGoogle Scholar
  6. 6.••
    Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safely of medical marijuana in selected neurologic disorders. Report of the guideline development subcommittee of the American academy of neurology. Neurology. 2014;82:1556–63. This is a systematic review of medical marijuana from 1948- Nov 2013 which addresses treatment of symptoms of MS; and also epilepsy and movement disorders.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Vemuri VK, Makriyannis A. Medical chemistry of cannabinoids. Clin Pharmacol Ther. 2015;97(6):553–8. doi: 10.1002/cpt.115.CrossRefPubMedGoogle Scholar
  8. 8.••
    Whiting PF, Wolff RF, Deshpande S, Nisio MD, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–73. doi: 10.1001/jama.2015.6358. This is a 2015 meta-analysis which looked at benefits and adverse effects of cannabinoids from 28 databases, since their inception to April 2015.CrossRefPubMedGoogle Scholar
  9. 9.
    Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. 2011;63:S240–52.CrossRefGoogle Scholar
  10. 10.•
    Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, et al. The cannabinoid use in progressive inflammatory brain disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis. Health Technol Assess. 2015;19:1–188. This is one of the largest studies in terms of patient enrollment and also has the longest duration of follow-up.CrossRefGoogle Scholar
  11. 11.
    Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404:84–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Heinzel-Gutenbrunner M, Vaney C, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004;10(4):417–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Makela P, Wade DT, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Fox P, Zajicek J, Sanders H, UKMS Research Group, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG, MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83(11):1125–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. 2007;14(3):290–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. 2010;32(5):451–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664–9.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler. 2012;18:219–28.CrossRefPubMedGoogle Scholar
  21. 21.
    Centonze D, Mori F, Kock G, et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci. 2009;30:531–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Wolfson TJ, Corey-Bloom J, Gamst A, Jin S, Marcotte TD, Bentley H, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ. 2012;184(10):1143–50. doi: 10.1503/cmaj.110837.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994;55:324–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58(9):1404–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. D-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. 1987;7:39–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler. 2006;12(5):639–45.CrossRefPubMedGoogle Scholar
  27. 27.
    Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122–31.CrossRefPubMedGoogle Scholar
  28. 28.
    Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Fife TD, Moawad H, Moschonas C, Shepard K, Hammond N. Clinical perspectives on medical marijuana (cannabis) for neurologic disorders. Neurol Clin Pract. 2015;5:344–51.CrossRefPubMedGoogle Scholar
  30. 30.
    Farrell M, Buchbinder R, Hall W. Should doctors prescribe cannabinoids? BMJ. 2014;348:g2737.CrossRefPubMedGoogle Scholar
  31. 31.
    Whiting PF et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313:2456–73.CrossRefPubMedGoogle Scholar
  32. 32.
    Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313:2474–83.CrossRefPubMedGoogle Scholar
  33. 33.
    Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65:812–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice—results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71:271–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Turcotte D et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis‐induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16:149–59.CrossRefPubMedGoogle Scholar
  36. 36.
    Di Marzo V, Centonze D. Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes. CNS Neurosci Ther. 2015;21:215–21.CrossRefPubMedGoogle Scholar
  37. 37.
    Ellis RJ et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2008;34:672–80.PubMedCentralCrossRefPubMedGoogle Scholar
  38. 38.
    Ware MA et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. Can Med Assoc J. 2010;182:E694–701.CrossRefGoogle Scholar
  39. 39.••
    Yadav V, Bever C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis. Report of the guideline development subcommittee of the American academy of neurology. Neurology. 2014;82:1083–92. doi: 10.1212/WNL.0000000000000250. This recent paper contains guidelines on various complementary and alternative medicines in MS, including cannabinoids.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.••
    Yadav V, Narayanaswami P. Complementary and alternative medical therapies in multiple sclerosis—the American academy of neurology guidelines: a commentary. Clin Ther. 2014;36(12):1972–8. doi: 10.1016/j.clinthera.2014.10.011. This recent paper contains guidelines on various complementary and alternative medicines in MS, including cannabinoids.CrossRefPubMedGoogle Scholar
  41. 41.
    Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. CMAJ. 2008;178(13):1669–78. doi: 10.1503/cmaj.071178.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Papathanasopoulos P, Messinis L, Lyros E, Kastellakis A, Panagis G. Multiple sclerosis, cannabinoids, and cognition. J Neuropsychiatry Clin Neurosci. 2008;20(1):36–51. doi: 10.1176/appi.neuropsych.20.1.36.CrossRefPubMedGoogle Scholar
  43. 43.
    Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and congnitive effects of theapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009;32(1):41–7. doi: 10.1097/WNF.0B013E3181633497.PubMedGoogle Scholar
  44. 44.
    Pavisian B, Macintosh BJ, Szilagyi G, Staines RW, O’Connor P, Feinstein A. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology. 2014;82(21):1879–87. doi: 10.1212/WNL.0000000000000446.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Hardeep Chohan
    • 1
  • Ariele L. Greenfield
    • 1
  • Vijayshree Yadav
    • 2
  • Jennifer Graves
    • 1
  1. 1.Department of NeurologyUniversity of California, San FranciscoSan FranciscoUSA
  2. 2.Department of NeurologyOregon Health and Science UniversityPortlandUSA

Personalised recommendations